Fenugreek extract as a natural therapy for dyslipidaemia: an in vivo study on rats
DOI:
https://doi.org/10.60988/p.v37i2S.213Keywords:
atorvastatin; dyslipidaemia; fenugreek extract; lipid profile; natural therapyAbstract
Dyslipidaemia is a major risk factor for cardiovascular disease, necessitating effective lipid-lowering interventions. This study investigates the lipid-modulating effects of fenugreek (Trigonella foenum-graecum) extract in comparison to atorvastatin, on rats, with a focus on dose-dependent responses. Male rats (n=150) were randomly assigned to five groups (n=30 per group): negative control (NC), positive control treated with atorvastatin (5–20 mg/kg), and three experimental groups receiving low (100 mg/kg), medium (250 mg/kg), or high (500 mg/kg) doses of fenugreek extract. Lipid profiles – including total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides (TG) – were assessed post-treatment using standard biochemical assays. Atorvastatin significantly reduced TC (75.33 ± 19.49 mg/dL, p<0.05) and LDL-cholesterol (26.93 ± 10.36 mg/dL, p<0.0001), while elevating HDL-cholesterol (55.20 ± 13.19 mg/dL, p<0.0001). Similarly, high-dose fenugreek extract significantly lowered TC (75.97 ± 32.58 mg/dL, p<0.05) and LDL-cholesterol (22.17 ± 10.11 mg/dL, p<0.0001), with a concomitant increase in HDL-cholesterol (57.90 ± 20.45 mg/dL, p<0.0001). No significant changes in TG levels were observed across the assessed groups. These findings suggest that the fenugreek extract, particularly at higher doses, exerts lipid-lowering effects comparable to atorvastatin, supporting its potential as a natural alternative or adjunctive therapy in the management of dyslipidaemia.
References
1. Srinivasa U.M., Naidu M.M. Fenugreek (Trigonella foenum-graecum L.) seed: promising source of nutraceutical. Stud. Nat. Prod. Chem. 71, 141–184, 2021. DOI: 10.1016/B978-0-323-91095-8.00014-3
2. Sun F., Yang X., Ma C., Zhang S., Yu L., Lu H., et al. The effects of diosgenin on hypolipidemia and its underlying mechanism: a review. Diabetes Metab. Syndr. Obes. 14, 4015–4030, 2021. DOI: 10.2147/DMSO.S326054
3. Fakhr L., Chehregosha F., Zarezadeh M., Chaboksafar M., Tarighat-Esfanjani A. Effects of fenugreek supplementation on the components of metabolic syndrome: a systematic review and dose-response meta-analysis of randomized clinical trials. Pharmacol. Res. 187, 106594, 2023. DOI: 10.1016/j.phrs.2022.106594
4. Eseberri I., Trepiana J., Léniz A., Gómez-García I., Carr-Ugarte H., González M., et al. Variability in the beneficial effects of phenolic compounds: a review. Nutrients 14(9), 1925, 2022. DOI: 10.3390/nu14091925
5. Martirossian A.N., Goldberg A.C. Management of patients with statin intolerance. Best Pract. Res. Clin. Endocrinol. Metab. 37(3), 101714, 2023. DOI: 10.1016/j.beem.2022.101714
6. Bonilha I., Luchiari B., Nadruz W., Sposito A.C. Very low HDL levels: clinical assessment and management. Arch. Endocrinol. Metab. 67(1), 3–18, 2023. DOI: 10.20945/2359-3997000000585